| Pharmaceutical Information |
| Drug Name |
Laronidase |
| Drug ID |
BADD_D01249 |
| Description |
Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. It contains 6 N-linked oligosaccharide modification sites. |
| Indications and Usage |
For the treatment of mucopolysaccharidosis |
| Marketing Status |
approved |
| ATC Code |
A16AB05 |
| DrugBank ID |
DB00090
|
| KEGG ID |
D04670
|
| MeSH ID |
Not Available
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D03LUN
|
| NDC Product Code |
68135-000; 58468-0070 |
| UNII |
WP58SVM6R4
|
| Synonyms |
Not Available |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
210589-09-6 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
